Oppenheimer began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report issued on Friday, AR Network reports. The brokerage set a “buy” rating and a $13.00 price target on the stock. Oppenheimer’s target price would indicate a potential upside of 60.30% from the stock’s previous close. A number of other brokerages have also recently […]
